Transgene . (NASDAQ:TRGNY)
Historical Stock Chart
From Sep 2019 to Sep 2024
Transgene Appoints Jean-Yves Bonnefoy as New Chief Scientific
Officer
STRASBOURG, France, Feb. 15 /PRNewswire-FirstCall/ -- Transgene (Nasdaq:
TRGNY; Euronext: FR0005175080) announced today the appointment of Dr. Jean-Yves
Bonnefoy as its new Chief Scientific Officer. He replaces Serge Braun who has
decided to pursue other opportunities outside of the Company.
Prior to joining Transgene, Jean-Yves Bonnefoy, 45, was Head of the Canceropole
Lyon Rhones-Alpes. From 1997 to 2002, he was Director of the Immunology Center
of the Pierre Fabre Group in Saint-Julien en Genevois, France. He previously
was responsible for the Immunology Department of the Biomedical Research
Institute of the Glaxo-Wellcome Group in Geneva, Switzerland. Jean-Yves
Bonnefoy holds a PhD in immunology from the Lyons Claude Bernard University and
has completed the Senior Management Program of the London Business School.
"We thank Serge Braun for his contribution to the development of Transgene,"
stated Philippe Archinard, Chief Executive Officer of Transgene. "We are
delighted to integrate Jean-Yves' immunology experience and background in the
infectiology and oncology fields. His arrival will allow us to reinforce
Transgene as a company dedicated to therapeutic vaccination."
About Transgene
Transgene, based in Strasbourg, France, is a biopharmaceutical company
dedicated to the discovery and development of therapeutic vaccines,
immunotherapy products, and delivery technologies for the treatment of diseases
for which there is no cure or adequate treatment at present, with a focus on
the treatment of cancer. Transgene has five products in clinical development,
two of which are in Phase II clinical trials, two in Phase I/II and one that
has completed Phase I clinical trial. Transgene's proprietary vector technology
platform consists of adenovirus and poxvirus vector families.
DATASOURCE: Transgene
CONTACT: Philippe Poncet, C.F.O. and Investors Relations, Transgene,
+33-3-88-27-91-01; Michael Long, Cohn & Wolfe, +1-415-365-8523, for Transgene;
Tiphaine Hecketsweiler, Image 7, +33-1-53-70-74-70, for Transgene
Web site: http://www.transgene.fr/